Subcutaneous Sarilumab in Patients With Rheumatoid Arthritis who Previously Received Subcutaneous Sarilumab or Intravenous Tocilizumab: An Open‐Label Extension of a Randomized Clinical Trial

Subcutaneous Sarilumab in Patients With Rheumatoid Arthritis who Previously Received Subcutaneous Sarilumab or Intravenous Tocilizumab: An Open‐Label Extension of a Randomized Clinical Trial

Objective This post hoc analysis evaluated the safety and efficacy of open‐label sarilumab in patients with rheumatoid arthritis (RA) who completed the phase III double‐blind ASCERTAIN study (NCT01768572) and switched from intravenous (IV) tocilizumab to subcutaneous (SC) sarilumab, or who continued...

Full description

Bibliographic Details
Main Authors:	Paul Emery, Hubert vanHoogstraten, Karthinathan Thangavelu, Erin Mangan, Gregory St John, Patrick Verschueren
Format:	Article
Language:	English
Published:	Wiley 2020-11-01
Series:	ACR Open Rheumatology
Online Access:	https://doi.org/10.1002/acr2.11188

Similar Items

Sarilumab: patient-reported outcomes in rheumatoid arthritis
by: Crotti C, et al.
Published: (2018-08-01)

Profile of sarilumab and its potential in the treatment of rheumatoid arthritis
by: Raimondo MG, et al.
Published: (2017-05-01)

Immunogenicity of Sarilumab Monotherapy in Patients with Rheumatoid Arthritis Who Were Inadequate Responders or Intolerant to Disease-Modifying Antirheumatic Drugs
by: Alvin F. Wells, et al.
Published: (2019-05-01)

New possibilities of drug therapy for rheumatoid arthritis: focus at sarilumab
by: D. E. Karateev, et al.
Published: (2019-11-01)

Inhibitor of biological effects of interleukin-6 sarilumab in treatment of rheumatoid arthritis
by: D. E. Karateev, et al.
Published: (2019-12-01)

Efficacy and safety of sarilumab in combination with csDMARDs or as monotherapy in subpopulations of patients with moderately to severely active rheumatoid arthritis in three phase III randomized, controlled studies
by: Mark C. Genovese, et al.
Published: (2020-06-01)

Patient-reported outcomes from a randomized phase III trial of sarilumab monotherapy versus adalimumab monotherapy in patients with rheumatoid arthritis
by: Vibeke Strand, et al.
Published: (2018-06-01)

Combination Therapy with Nintedanib and Sarilumab for the Management of Rheumatoid Arthritis Related Interstitial Lung Disease
by: Caterina Vacchi, et al.
Published: (2020-01-01)

Clinical evaluation of the safety, efficacy and tolerability of sarilumab in the treatment of moderate to severe rheumatoid arthritis
by: Pelechas E, et al.
Published: (2019-09-01)

Sarilumab use in severe SARS-CoV-2 pneumonia
by: Elisa Gremese, et al.
Published: (2020-10-01)

Sarilumab and adalimumab differential effects on bone remodelling and cardiovascular risk biomarkers, and predictions of treatment outcomes
by: Cem Gabay, et al.
Published: (2020-04-01)

Sarilumab plus methotrexate in patients with active rheumatoid arthritis and inadequate response to methotrexate: results of a randomized, placebo-controlled phase III trial in Japan
by: Yoshiya Tanaka, et al.
Published: (2019-03-01)

Correction to: Sarilumab plus methotrexate in patients with active rheumatoid arthritis and inadequate response to methotrexate: results of a randomized, placebo-controlled phase III trial in Japan
by: Yoshiya Tanaka, et al.
Published: (2019-04-01)

Population Pharmacodynamic Model of Neutrophil Margination and Tolerance to Describe Effect of Sarilumab on Absolute Neutrophil Count in Patients with Rheumatoid Arthritis
by: Pavel Kovalenko, et al.
Published: (2020-07-01)

The efficacy and safety of sarilumab, fully human monoclonal antibodies against interleukin 6 receptor, in rheumatoid arthritis: new evidence
by: E. L. Nasonov, et al.
Published: (2019-11-01)

Tocilizumab therapy for COVID-19: A comparison of subcutaneous and intravenous therapies
by: Monica A. Kaminski, et al.
Published: (2020-12-01)

Subcutaneous Sarilumab in hospitalised patients with moderate-severe COVID-19 infection compared to the standard of care (SARCOVID): a structured summary of a study protocol for a randomised controlled trial
by: Rosario Garcia-Vicuña, et al.
Published: (2020-09-01)

Tocilizumab Effectiveness After Switching from Intravenous to Subcutaneous Route in Patients with Rheumatoid Arthritis: The RoSwitch Study
by: Jean Darloy, et al.
Published: (2019-01-01)

Budget impact analysis of sarilumab for the treatment of rheumatoid arthritis in patients with an inadequate response to conventional synthetic DMARD or TNF inhibitor therapies
by: Ferrufino CP, et al.
Published: (2018-11-01)

High levels of interleukin-6 in patients with rheumatoid arthritis are associated with greater improvements in health-related quality of life for sarilumab compared with adalimumab
by: Vibeke Strand, et al.
Published: (2020-10-01)

Budget impact analysis of sarilumab for the treatment of rheumatoid arthritis in patients with an inadequate response to conventional synthetic DMARD or TNF inhibitor therapies [Corrigendum]
by: Ferrufino CP, et al.
Published: (2019-01-01)

Efficacy and safety of sarilumab in combination with methotrexate in patients with active rheumatoid arthritis and inadequate effect of methotrexate monotherapy (results of phase III MOBILITY study)
by: E. L. Nasonov, et al.
Published: (2019-05-01)

Sarilumab monotherapy compared with adalimumab monotherapy for the treatment of moderately to severely active rheumatoid arthritis: an analysis of incremental cost per effectively treated patient
by: Fournier M, et al.
Published: (2019-02-01)

Accelerated subcutaneous nodulosis in patients with rheumatoid arthritis treated with tocilizumab: a case series
by: Rossella Talotta, et al.
Published: (2018-06-01)

Resolution of the National Multidisciplinary Research Council of Experts on the place of anti-interleukin-6 receptor monoclonal antibodies (Sarilumab) in the treatment of patients with rheumatoid arthritis and comorbidity
by: article Editorial
Published: (2020-06-01)

Potential patient benefit of a subcutaneous formulation of tocilizumab for the treatment of rheumatoid arthritis: a critical review
by: Besada E
Published: (2014-08-01)

Drug delivery options to increase patient adherence and satisfaction in the management of rheumatoid arthritis – focus on subcutaneous tocilizumab
by: Nakashima Y, et al.
Published: (2014-07-01)

Use of subcutaneous tocilizumab to prepare intravenous solutions for COVID-19 emergency shortage: Comparative analytical study of physicochemical quality attributes
by: Natalia Navas, et al.
Published: (2020-12-01)

Subcutaneous administration of tocilizumab is effective in myointimal hyperplasia remodelling in refractory Takayasu arteritis
by: A. Lo Gullo, et al.
Published: (2017-12-01)

Efficacy of subcutaneous tocilizumab in patients with rheumatoid arthritis and systemic sclerosis overlap syndrome: a report of two cases and review of the literature
by: Hiroki Wakabayashi, et al.
Published: (2019-04-01)

Outcomes and biomarker analyses among patients with COVID-19 treated with interleukin 6 (IL-6) receptor antagonist sarilumab at a single institution in Italy
by: Roberto Parella, et al.
Published: (2020-07-01)

Correction: Outcomes and biomarker analyses among patients with COVID-19 treated with interleukin 6 (IL-6) receptor antagonist sarilumab at a single institution in Italy
by: Vandana Sachdev, et al.
Published: (2020-07-01)

Efficacy and safety of early treatment with sarilumab in hospitalised adults with COVID-19 presenting cytokine release syndrome (SARICOR STUDY): protocol of a phase II, open-label, randomised, multicentre, controlled clinical trial
by: Antonio Luque-Pineda, et al.
Published: (2020-11-01)

Payer Perspectives on Intravenous versus Subcutaneous Administration of Drugs
by: Epstein RS
Published: (2021-09-01)

Sarilumab versus standard of care for the early treatment of COVID-19 pneumonia in hospitalized patients: SARTRE: a structured summary of a study protocol for a randomised controlled trial
by: Antonio F. Caballero Bermejo, et al.
Published: (2020-09-01)

The subcutaneous nodules and the visceral lesions of chronic rheumatoid arthritis
by: Horwitz, Marshall
Published: (2017)

Pharmacokinetics of Tildipirosin in Ewes after Intravenous, Intramuscular and Subcutaneous Administration
by: Juan Sebastián Galecio, et al.
Published: (2020-08-01)

Intravenous Valproate versus Subcutaneous Sumatriptan in Acute Migraine Attack
by: Fahmida Ghaderibarmi, et al.
Published: (2015-10-01)

Comparing the Effect of Subcutaneous and Intravenous Tramadol Injection on Postoperative Pain
by: Hamid Hajigholam Hajigholam Saryazdi, et al.
Published: (2011-03-01)

Scleromyxedema with Subcutaneous Nodules: Successful Treatment with Thalidomide and Intravenous Immunoglobulin
by: M. Dolenc-Voljč, et al.
Published: (2013-11-01)

Cannot write session to /tmp/vufind_sessions/sess_hl22udj0f187k24krerud51u4m